CureSearch combats the loss of promising scientists from the field by providing significant financial support to investigators early in their research career. Early-career investigators are the most vulnerable to federal funding shortages, and they rely more than ever on the support of private foundations like CureSearch in order to continue their research.
These grants are limited to truly transformational science designed to deliver the next generation of cancer treatment. Starting in 2012, CureSearch supported 12 Young Investigators for two years in research areas with high risk and poor outcomes: relapsed ALL, AML, brain tumors, Ewing sarcoma, hepatoblastoma, Hodgkin disease, neuroblastoma, non-Hodgkin lymphoma, rhabdomyosarcoma, survivorship/late effects, adolescent and young adult cancer, and Wilms tumor. Encouraged by this success, CureSearch awarded 6 new grants in 2015 for 3 years with more than double the funds, allowing more young researchers to establish a sustainable model from the outset of their research.
New Young Investigator Grants (2018-2020)
CureSearch is launching its next round of Young Investigator Program funding. The 2017 program aligns with our Research Strategy supporting training and education of early career scientists in pediatric oncology drug development. Projects will focus on drug discovery and pre-clinical drug development for 6 high-risk disease areas (leukemia, brain, bone, neuroblastoma, sarcoma, other demonstrably high-risk tumors). Awardees are encouraged to participate in a drug development educational program. The application window closed in October 2017. Awards will be announced by March 2018.